PUMA BIOTECHNOLOGY, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $119.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2021-03-01
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2020-12-31 was $39.00K.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2020-09-30 was $75.00K, a 31.82% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2020-06-30 was $0.00, a 100.00% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2020-03-31 was $5.00K, a 99.28% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2020 was $119.00K, a 88.04% decline from fiscal 2019.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2019 was $995.00K, a 80.35% decline from fiscal 2018.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2018 was $5.06M, a 81.38% decline from fiscal 2017.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2017 was $27.18M, a 1898.90% increase from fiscal 2016.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2020-12-31 | $39.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $114.00K derived: sum of 2 quarters · filed 2021-03-01 | $114.00K derived: sum of 3 quarters · filed 2021-03-01 | $119.00K 10-K · filed 2021-03-01 |
| 2020-09-30 | $75.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $75.00K derived: sum of 2 quarters · filed 2020-11-05 | $80.00K 10-Q · filed 2020-11-05 | $80.00K derived: sum of 4 quarters · filed 2021-03-01 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $5.00K 10-Q · filed 2020-08-06 | $5.00K derived: sum of 3 quarters · filed 2021-03-01 | $115.00K derived: sum of 4 quarters · filed 2021-03-01 |
| 2020-03-31 | $5.00K 10-Q · filed 2020-05-07 | $5.00K derived: sum of 2 quarters · filed 2021-03-01 | $115.00K derived: sum of 3 quarters · filed 2021-03-01 | $305.00K derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $110.00K derived: sum of 2 quarters · filed 2021-03-01 | $300.00K derived: sum of 3 quarters · filed 2021-03-01 | $995.00K 10-K · filed 2021-03-01 |
| 2019-09-30 | $110.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $300.00K derived: sum of 2 quarters · filed 2019-11-07 | $995.00K 10-Q · filed 2019-11-07 | $1.05M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $190.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $885.00K 10-Q · filed 2019-08-09 | $937.00K derived: sum of 3 quarters · filed 2021-03-01 | $1.40M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $695.00K 10-Q · filed 2019-05-10 | $747.00K derived: sum of 2 quarters · filed 2021-03-01 | $1.21M derived: sum of 3 quarters · filed 2021-03-01 | $3.50M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $52.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $517.00K derived: sum of 2 quarters · filed 2021-03-01 | $2.81M derived: sum of 3 quarters · filed 2021-03-01 | $5.06M 10-K · filed 2021-03-01 |
| 2018-09-30 | $465.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $2.75M derived: sum of 2 quarters · filed 2018-11-05 | $5.01M 10-Q · filed 2018-11-05 | $13.83M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-06-30 | $2.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $4.55M 10-Q · filed 2018-08-09 | $13.37M derived: sum of 3 quarters · filed 2020-02-28 | $27.40M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-03-31 | $2.26M 10-Q · filed 2018-05-10 | $11.07M derived: sum of 2 quarters · filed 2020-02-28 | $25.11M derived: sum of 3 quarters · filed 2020-02-28 | $28.96M derived: sum of 4 quarters · filed 2020-02-28 |
| 2017-12-31 | $8.82M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $22.85M derived: sum of 2 quarters · filed 2020-02-28 | $26.70M derived: sum of 3 quarters · filed 2020-02-28 | $27.18M 10-K · filed 2020-02-28 |
| 2017-09-30 | $14.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $17.89M derived: sum of 2 quarters · filed 2017-11-09 | $18.37M 10-Q · filed 2017-11-09 | $18.46M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $3.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $4.33M 10-Q · filed 2017-08-09 | $4.43M derived: sum of 3 quarters · filed 2019-03-01 | $4.78M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | $481.00K 10-Q · filed 2017-05-10 | $573.00K derived: sum of 2 quarters · filed 2019-03-01 | $921.00K derived: sum of 3 quarters · filed 2019-03-01 | $921.00K derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | $92.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $440.00K derived: sum of 2 quarters · filed 2019-03-01 | $440.00K derived: sum of 3 quarters · filed 2019-03-01 | $1.36M 10-K · filed 2019-03-01 |
| 2016-09-30 | $348.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $348.00K derived: sum of 2 quarters · filed 2016-11-09 | $1.27M 10-Q · filed 2016-11-09 | $10.05M derived: sum of 4 quarters · filed 2018-03-09 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $920.00K 10-Q · filed 2016-08-09 | $9.70M derived: sum of 3 quarters · filed 2018-03-09 | $24.40M derived: sum of 4 quarters · filed 2018-03-09 |
| 2016-03-31 | $920.00K 10-Q · filed 2016-05-10 | $9.70M derived: sum of 2 quarters · filed 2018-03-09 | $24.40M derived: sum of 3 quarters · filed 2018-03-09 | $40.36M derived: sum of 4 quarters · filed 2018-03-09 |
| 2015-12-31 | $8.78M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $23.48M derived: sum of 2 quarters · filed 2018-03-09 | $39.44M derived: sum of 3 quarters · filed 2018-03-09 | $102.15M 10-K · filed 2018-03-09 |
| 2015-09-30 | $14.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $30.66M derived: sum of 2 quarters · filed 2015-11-09 | $93.37M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $15.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $78.67M 10-Q · filed 2015-08-10 | ||
| 2015-03-31 | $62.71M 10-Q · filed 2015-05-11 | |||
| 2014-12-31 | $74.11M 10-K · filed 2017-03-01 | |||
| 2013-12-31 | $23.52M 10-K · filed 2016-02-29 | |||
| 2012-12-31 | $190.00K 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |